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Attenuated vaccinia virus (VACV) vectors are considered prime vaccine candidates for use
in immunotherapy of infectious disease. In spite of this, recent data show that the level of
attenuation may hamper the efﬁcient generation of protective CD8 T cells. This suggests
that additional adjuvant-like activities may need to be combined with attenuated VACV for
optimal vaccination. Stimulatory reagents to theTNFR family molecule 4-1BB (CD137) may
represent such an adjuvant for vaccination. Previous murine studies have found that 4-
1BB can participate in optimal priming of effector and memory CD8T cells in response to
several virus infections, and concordantly direct stimulation of 4-1BBwith agonist reagents
effectively boosts the CD8 T cell response against those viruses. In contrast, we recently
reported that 4-1BB plays no role in the response to a virulent strain of VACV, questioning
whether agonists of 4-1BBwill be useful adjuvants for vaccination withVACV vectors. Here
we show that agonist anti-4-1BB strongly enhanced the primary viral-speciﬁc effector CD8
T cell response during infection with live virulent VACV and attenuated VACV, and during
immunization with VACV peptides given in IFA. However, accumulation of memory CD8
T cellswas enhanced only following infectionwith virulentVACV orwith peptide vaccination,
but not with attenuated VACV, correlating in part with more transient expression of 4-1BB
on CD8 T cells with attenuated virus. Our data therefore suggest that 4-1BB may be a
promising candidate for targeting as an adjuvant for short-term enhancement of CD8T cell
responses withVACV vaccine strategies, but additional receptors may need to be engaged
with 4-1BB to allow long-term CD8T cell immunity with attenuated VACV vectors.
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INTRODUCTION
A challenge for the development of vaccines and vectors for
immunotherapy of infectious disease is to allow safe delivery
of T cell epitopes that will induce efﬁcient short or long-term
cell-mediated immune responses. In particular, being able to pro-
mote CD8 T cell populations that can eliminate cells infected
with viruses or intracellular pathogens is an attractive goal that
is being recognized as a desirable component of any vaccine.
This has led to viral vectors or subunit vaccines being consid-
ered for diseases such as HIV, hepatitis, and malaria. While many
researchers might acknowledge that live vaccines or viral vectors
are the best way to induce cell-mediated immunity and CD8 T
cell responses, there is concern about the safety of live vaccines
and in particular about adverse side effects that might result with
viruses or viral vectors that replicate strongly and spread within
the host. In this regard, the study of vaccinia viruses (VACV) is
of relevance as they are considered to be prime candidates for use
in immunotherapy. However, the VACV strains used during the
eradication of smallpox induced severe adverse effects in immuno-
compromised patients, leading to the development of attenuated
strains for clinical use. Although attenuated vaccines/vectors, that
replicate poorly or do not replicate at all, solve the latter issue,
recent data are questioning whether these will induce strong,
optimal, and/or long-lasting T cell responses, particularly in the
CD8 compartment (Morgan et al., 1988; Cleghorn et al., 2007;
Karem et al., 2007; Peters et al., 2007; Thongcharoen et al., 2007;
Ferrier-Rembert et al., 2008; Midgley et al., 2008). The rationale
here is that the magnitude of the T cell response is often pro-
portionately related to the amount of antigenic epitopes that are
available and presented over time (Wherry et al., 2002; Liu et al.,
2007, 2010; Blair et al., 2011; Salek-Ardakani et al., 2011a). Thus,
poor viral replication will translate into poor induction of T cell
immunity.
The question is then whether a non-replicating or attenuated
viral vector, or isolated antigens, can be used together with an
adjuvant mechanism that allows effective and optimal induction
of CD8 T cell responses while still maintaining the safety desirable
in such a vaccine. Various data published over the past 10 years has
suggested that targeting stimulatory/pro-inﬂammatory members
of the TNFR superfamily might provide this adjuvant-like activ-
ity (Watts, 2005; Salek-Ardakani and Croft, 2010; Goulding et al.,
2011). For example, we showed that exogenous stimulation of the
OX40 receptor (CD134), with an agonist reagent, could effectively
boost CD8 T cell priming with an attenuated VACV virus, to the
extent that the induced populations engendered protection against
a normally lethalVACV infection that did not rely on other protec-
tive mechanisms such as antibody (Salek-Ardakani et al., 2011a,b).
The rationale for targeting OX40 was that a highly virulent strain
of VACV resulted in engagement of the endogenous OX40 recep-
tor that is expressed on activated CD8 T cells, and this led to
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the generation of greatly elevated frequencies of primary effector
and memory CD8 T cell populations compared to those induced
with attenuatedVACVvariants (Salek-Ardakani et al., 2008, 2011a;
Goulding et al., 2011). 4-1BB (CD137) is another TNFR molecule
that can be induced on activated CD8 T cells, as well as CD4 T
cells, NK cells, NKT cells, and some dendritic cells (Croft, 2009;
Croft et al., 2012). Endogenous 4-1BB/4-1BBL interactions have
been shown to participate in priming of virus-speciﬁc CD8 T
cells during infection with inﬂuenza virus (Bertram et al., 2002,
2004), LCMV (Tan et al., 1999, 2000) and HSV (Seo et al., 2003),
and correspondingly targeting 4-1BB with an agonist antibody, or
incorporation of 4-1BBL into a vaccine vector, allowed enhanced
CD8 responses to these viruses (Halstead et al., 2002; Kim et al.,
2005; Zhang et al., 2007; Moraes et al., 2011; Vezys et al., 2011).
Altogether this implies that knowledge of the endogenous use of a
stimulatory receptor might be generally applicable for determin-
ing what molecule might be amenable for targeting to enhance
vaccine efﬁcacy with attenuated virus vectors or with isolated viral
antigens.
In contrast to the positive endogenous activities reported above,
we recently found no role for 4-1BB or 4-1BBL in generating pri-
mary effector or memory CD8 T cells elicited by the virulent
Western Reserve strain of VACV (VACV-WR; Zhao and Croft,
2012). This then presented an interesting scenario to test whether
targeting a receptor that was not normally active during an anti-
viral response could still be efﬁcacious in enhancing CD8 T cell
immunity to that virus. Here, we assessed the effects of an agonist
antibody to 4-1BB in promoting CD8 T cell responses to VACV
variants and VACV epitopes.
MATERIALS AND METHODS
MICE
Eight-week-old female C57BL/6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). Average starting weight of
these mice was 21.45 ± 0.93 g (n = 42). The studies reported here
conform to the animal Welfare Act and the NIH guidelines for the
care and use of animals in biomedical research. All experiments
were conducted following the guidelines of the La Jolla Institute
for Allergy and Immunology’s Institutional Animal Care and Use
Committee.
VIRUSES
The VACV Western Reserve and Lister (VACV-Lister) strains were
purchased from theAmerican Type Culture Collection (Manassas,
VA), grown in HeLa cells, and titered on VeroE6 cells.
IMMUNIZATION PROTOCOLS
Mice were infected i.p. with 2 × 104 or 2 × 105 PFU of VACV,
or were immunized s.c. at the base of the tail with 2 μg or
10 μg/mouse of various CD8 T cell peptide epitopes emulsiﬁed
in IFA together with a hepatitis B virus core 128–140 (TPPAYRPP-
NAPIL) epitope. Mice were also injected with 25 or 100 or 150 μg
agonist anti-4-1BB (clone 3H3) or rat IgG (Chemicon) as control
on the days stated in the ﬁgure legends.
VACV INTRANASAL CHALLENGE
Mice were anesthetized by inhalation of isoﬂurane and inoculated
by the intranasal route with 3.5 × 106 of VACV-WR. Mice were
weighed daily for 2 weeks following challenge and were euthanized
when they lost more than 25% of their initial body weight and this
was loss was maintained for greater than 24 h. Body weight was
calculated as percentage of the mean weight for each group on the
day of challenge.
PEPTIDES AND TETRAMERS
Vaccinia virus peptide epitopes used in this study were pre-
dicted and synthesized as described previously (Tscharke et al.,
2005; Moutaftsi et al., 2006); B8R (20-27; TSYKFESV), B2R (54-
62; YSQVNKRYI), A23R (297-305; IGMFNLTFI). N2L (60-68;
FLMMNKDEL), B16R (275-283; ISVANKIYM), MHC/peptide
tetramers for the VACV-WR epitope B8R (20-27; TSYKFESV)/
H-2Kb, which were conjugated to allophycocyanin, were obtained
from the National Institutes of Health Tetramer Core facility
(Emory University, Atlanta, GA).
IMMUNOFLUORESCENCE LABELING
Tetramer-positive cells were identiﬁed after gating on CD8 T
cells with anti-CD8 (PerCP) and co-staining with anti-CD44
(PE) (BD Biosciences). 4-1BB was visualized with biotin-labeled
anti-4-1BB (Biolegend) followed by FITC-labeled streptavidin
(Molecular Probes). Intracellular staining for cytokine production
in T cells was performed as previously described (Salek-Ardakani
et al., 2008), with some modiﬁcations. Brieﬂy, after lysing RBC,
splenocytes from infected mice were resuspended in RPMI-1640
medium (Gibco) supplementedwith 10%FCS (Omega Scientiﬁc),
1% L-glutamine (Invitrogen), 100 μg/ml streptomycin, 100 U/ml
penicillin and 50 μM 2-mercaptoethanol (Sigma). 1–2 × 106 cells
were plated in round-bottomed 96-well microtiter plates in 200 μl
with medium or the indicatedVACV peptides at 1 μg/ml for 1 h at
37◦C. GolgiPlug (BD Biosciences) was then added to the cultures
according to the manufacture’s instructions and the incubation
continued for 6–9 h. Cells were stained with anti-CD8 (PerCP)
and CD62L (PE), followed by ﬁxation with cytoﬁx/cytoperm (BD
Biosciences) for 20 min at 4◦C. Fixed cells were subjected to intra-
cellular cytokine staining in BD Perm/Wash buffer for 30 min
at 4◦C. Anti-TNF (FITC) and IFN-γ (APC) were obtained from
e-Bioscience and used at a 1:100 dilution. Samples were ana-
lyzed for their proportion of cytoplasmic cytokines after gating on
CD8+CD62Llow T cells by FACSCaliburTM ﬂow cytometer using
CellQuest (BD Biosciences) and FlowJo software (Tree Star, san
Carlos, CA).
STATISTICAL ANALYSIS
Unless otherwise indicated, data represent the means ± SEM. Stu-
dent’s t-test was used to determine statistical signiﬁcance versus
the control group. *p < 0.05.
RESULTS
We previously found that endogenous 4-1BB/4-1BBL interac-
tions played no apparent role in driving the CD8 T cell response
following an infection with the VACV-WR (Zhao and Croft,
2012). However, we noted that 4-1BB was induced on VACV
epitope-reactive CD8 T cells during the infection, apparent by
day 2 and maintained for approximately 5 days (Zhao and Croft,
2012). This strong and prolonged expression of 4-1BB suggested
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that agonist reagents that targeted this molecule might still rep-
resent a means to boost CD8 T cell priming and be of potential
use to augment immunity of relevance to smallpox infection or
if VACV was used as a vaccine vehicle. To test this, mice were
infected with VACV-WR and injected with an agonist antibody
to 4-1BB, 1 day after infection to coincide with expression of the
receptor. Even though VACV-WR induces a strong CD8 T cell
response (Salek-Ardakani et al., 2011a), a single high dose of the
agonist (100 μg) greatly enhanced (by four- to ﬁvefold) the accu-
mulation of primary effector CD8 T cells on day 7 in lymphoid
organs, determined by ﬂow analysis with a tetramer of the immun-
odominant peptide B8R (Figure 1A). Analysis of T cell reactivity
further conﬁrmed this after assessing the frequency of CD8 T cells
capable of making IFN-γ alone, TNF alone, or both cytokines,
following restimulation with B8R peptide in vitro (Figure 1B).
The stimulatory effect of anti-4-1BB was not limited to the
immunodominant CD8 T cell population as the frequency of sev-
eral subdominant effector populations was similarly boosted four-
to ﬁvefold (Figure 1B, A23R, B2R). These data differ from prior
studies of inﬂuenza where anti-4-1BB primarily augmented T cell
responses to subdominant epitopes (Halstead et al., 2002). Increas-
ing the dose of anti-4-1BB to 150 μg/mouse showed no further
increase in the primary CD8 T cell response (not shown), and a
lower dose of 25 μg/mouse still signiﬁcantly augmented priming
but generally to a proportionately lesser extent than 100μg/mouse
(Figure 1B). No difference was observed in the mean ﬂuorescence
intensity of staining for IFN-γ and TNF between the control and
anti-4-1BB-treated groups (not shown) implying 4-1BB signaling
FIGURE 1 | Anti-4-1BB augments primary CD8T cell responses to
VACV-WR.WT mice were infected i.p. with VACV-WR (2 × 104 PFU/mouse)
and treated with 0, 25, or 100 μg agonist anti-4-1BB or control antibody on
day 1 post-infection. Seven days after infection, (A) Cells from spleen
and peripheral lymph nodes (LN) were stained with anti-CD8, -CD44, and
B8R-tetramer.Top: Representative dot plots of gated CD8+ cells. The
numbers indicate the percentage of CD8+CD44+B8R-tetramer-positive cells.
Bottom: Total number of CD8+CD44+B8R-tetramer-positive cells in the
spleen and LN were calculated. (B) Splenocytes were stimulated with B8R,
A23R, or B2R peptide, followed by staining for intracellular IFN-γ and
TNF. Total numbers of CD8+IFN-γ+ (top), CD8+TNF+ (middle), and
CD8+IFN-γ+TNF+ cells (bottom) were calculated. (C)Total splenic CD8T cells
numbers were determined. (D) Lung cells were stimulated with B8R, A23R,
or B2R peptide, followed by staining for intracellular IFN-γ. Total numbers of
CD8+IFN-γ+ cells were calculated. Data represent mean value ± SEM from
n = 4 mice. Similar results were reproduced in two separate experiments.
The Student’s t -test was used to determine statistical signiﬁcance.
*p < 0.05.
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primarily augmented expansion but not differentiation of the
CD8 T cells. We also found that total CD8 T cells numbers
increased following the antibody treatment (Figure 1C). These
data correlate with prior data demonstrating the ability of 4-
1BB to regulate division and survival of CD8 T cells (Takahashi
et al., 1999; Cannons et al., 2001; Cooper et al., 2002; Lee et al.,
2002, 2003). To determine if 4-1BB signaling led to accumula-
tion of virus-reactive T cells in other organs, lungs were analyzed
and consistent with the prior results anti-4-1BB also enhanced
the number of CD8 effector T cells making IFN-γ in this organ
(Figure 1D).
To assess whether targeting 4-1BB promoted greater develop-
ment of CD8 T cell memory, responses were assessed on day
35 when stable populations arise after VACV infection (Salek-
Ardakani et al., 2008, 2011a). The frequency of memory CD8
T cells was again strongly boosted in mice injected with anti-4-
1BB regardless of epitope-reactivity, and including polyfunctional
T cells making both IFN-γ and TNF, as well as those making
only IFN-γ or TNF (Figure 2A). In this case, the lower dose
of anti-4-1BB was overall more effective in that fewer memory
CD8 T cells were induced in mice treated with 100 μg of anti-
body, particularly within the B8R-reactive population. Similarly,
total CD8 T cells numbers were increased following treatment
with the lower dose of antibody (Figure 2B). Thus, targeting 4-
1BB allows the more effective development of high frequencies
of VACV-reactive effector and memory CD8 T cells during an
infection with VACV-WR. Prior studies of anti-4-1BB in naïve
mice demonstrated that a high dose (200 μg) resulted in a num-
ber of adverse events, including splenomegaly, lymphadenopathy,
and hepatomegaly (Niu et al., 2007). In our experiments, we did
observe splenomegaly in excess of that normally induced by the
virus (approximately twofold more total spleen cells) at day 7,
however, this was not seen at day 35 (not shown). The mice also
showed no visible signs of adverse events based on daily moni-
toring during the studies (e.g., no weight loss, rufﬂed hair, lack
of movement) and groups of mice that were not sacriﬁced for
analyses survived over 18 months following anti-4-1BB treatment
comparable to control antibody-treated groups.
We next tested whether stimulation of 4-1BB would similarly
promote enhanced CD8 T cell responses to an attenuated VACV.
VACV-Lister is signiﬁcantly impaired in its ability to replicate
compared to VACV-WR (Salek-Ardakani et al., 2011a), at least in
part due to differential expression of genes or gene products that
block innate immunity (Kettle et al., 1995; Alcami et al., 2000).
Furthermore, and in contrast to VACV-WR, VACV-Lister given
systemically, as in the protocols used here, cannot induce sufﬁcient
FIGURE 2 | Anti-4-1BB augments memory CD8T cell responses to
VACV-WR.WT mice were infected i.p. with VACV-WR (2 × 104 PFU/mouse)
and treated with 0, 25 or 100 μg anti-4-1BB on day 1 post-infection. Thirty-ﬁve
days after infection, (A) Splenocytes were stimulated with B8R, A23R, or
B2R peptide, and stained for intracellular IFN-γ andTNF. Total numbers of
CD8+IFN-γ+ (top), CD8+TNF+ (middle), and CD8+IFN-γ+TNF+ cells
(bottom) were calculated. (B)Total splenic CD8T cell numbers were
calculated. Data represent mean value ± SEM from n = 4 mice. Similar
results were reproduced in two separate experiments. Statistical signiﬁcance.
*p < 0.05.
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numbers of memory CD8 T cells to protect against a subsequent,
normally lethal, infection with VACV-WR (Salek-Ardakani et al.,
2011a). During infection with VACV-Lister we observed 4-1BB to
be expressed on a large subset of B8R-reactive CD8 T cells at day 5
but it was down-regulated by day 7 (Figure 3A), in contrast to our
prior observation with VACV-WR where ∼30% of B8R-reactive
T cells still expressed 4-1BB on day 7 (Zhao and Croft, 2012). We
could not assess expression on B8R-tetramer-positive CD8 cells at
an earlier time due to the low number induced by VACV-Lister.
However, 4-1BB was up-regulated on a proportion of all effec-
tor/memory phenotype CD8 T cells (CD44-high-CD62L-low) as
early as day 3, peaked at day 5, and was substantially reduced
by day 7. Because 4-1BB is not constitutively expressed, many
of these cells were likely reactive with other virus epitopes. Col-
lectively this suggests that 4-1BB was only transiently expressed
in response to Lister but was available as a target for the agonist
antibody. Anti-4-1BB was again injected 1 day after VACV-Lister
infection and primary effector CD8 T cells quantitated at the peak
FIGURE 3 | Anti-4-1BB enhances the frequency of primary effector
CD8T cells after vaccination withVACV-Lister. Mice were infected i.p.
with 2.5 × 105 PFU/mouse of VACV-Lister. One day later, mice were
treated with 25 μg (A–D) or 100 μg (B) control rat IgG or anti-4-1BB and
responses assessed on day 8. (A) Gated CD8+CD44+ cells and
B8R-tetramer-positive CD8+ cells in spleens were stained for 4-1BB
expression on days 3, 5, and 7. (B) Spleen (upper panel) and lung
(lower panel) cells were stained with CD8, CD44, and B8R tetramer (left).
Total numbers of CD8+ B8R-tetramer-positive cells were calculated in spleen
(right). (C,D) CD8T cell functionality in the spleen (C) and lung (D) was
assessed by intracellular IFN-γ staining after stimulation with the indicated
VACV peptides. Top: Representative plots of cytokine staining, gating on
CD8+ T cells. Bottom: Total numbers of CD8+ IFN-γ+ cells per tissue. The
results are means and SEM (n = 4 mice/group) from one experiment. Similar
results were obtained in two separate experiments. Statistical signiﬁcance.
*p < 0.05.
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of the response on day 8. As with the response to VACV-WR, tar-
geting 4-1BB resulted in a greater expansion of the B8R-reactive
CD8 T cell population in the lymphoid organs as measured by
tetramer analysis and intracellular cytokine staining, and also
promoted enhanced accumulation of other epitope-speciﬁc pop-
ulations (A23R, B2R) assessed by intracellular cytokine staining
(Figures 3B–D). This was not restricted to the lymphoid organs
as signiﬁcantly greater numbers of VACV-speciﬁc CD8T cells were
visualized in the lungs. The effect of anti-4-1BB with VACV-Lister
was generally similar to that observed with VACV-WR infection
(three- to sixfold enhancement) and again primarily at the level
of clonal expansion as production of cytokines (based on MFI)
was largely comparable between the control and agonist antibody
groups (Figures 3C,D, IFN-γ shown, TNF not shown). In this
case, the dose of the antibody did not appreciably alter the extent
to which expansionwas affected in that a similar response was seen
with 25 μg compared to 100 μg (Figure 3B and not shown).
Surprisingly, when the memory CD8 T cell response to VACV-
Lister was assessed, we observed no positive effect of anti-4-1BB
treatment. The number of VACV-speciﬁc CD8 T cells was not
enhanced in VACV-Lister infected mice when analyzed after 35
days (Figure 4), in contrast to the results in VACV-WR infected
FIGURE 4 | Anti-4-1BB treatment does not enhance CD8T cell
memory toVACV-Lister. Mice were infected i.p. with 2.5 × 105 PFU/
mouse of VACV-Lister. One day later, mice were treated with 25 μg
(A–C) or 100 μg (A) of control rat IgG or anti-4-1BB and responses
assessed after 35 days. (A) Spleen (upper panel) and lung (lower panel)
cells were stained with CD8, CD44, and B8R tetramer (left). Total numbers
of CD8+ B8R-tetramer-positive cells in spleens (right). (B,C) CD8T cell
functionality in the spleen (B) and lung (C) was assessed by intracellular
IFN-γ staining after stimulation with the indicated VACV peptides. Top:
Representative plots of cytokine staining, gating on CD8+ T cells.
Bottom: Total numbers of CD8+ IFN-γ+ cells per tissue. The results are
means and SEM (n = 4 mice/group) from one experiment. Similar results
were obtained in two separate experiments. Statistical signiﬁcance.
*p < 0.05.
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mice (see Figure 2). This was regardless of location assayed, and
dose of anti-4-1BB injected. Collectively, these data suggest that
targeting 4-1BB may be a useful method for augmenting the accu-
mulation of viral antigen-speciﬁc CD8 T cells during infection
with a VACV or VACV vector, but that the level of attenuation
of the virus might determine whether the boosted response is
maintained over time.
Lastly, we determined whether targeting 4-1BB could promote
protective CD8 T cell populations during vaccination with VACV
antigens. Anti-4-1BB has previously been shown to boost memory
generation with a non-viral peptide vaccination scheme (Myers
et al., 2006). In our study, mice were immunized with the immun-
odominant VACV epitope, B8R, mixed in IFA, and 1 day later
injected with 25 or 150 μg anti-4-1BB. 4-1BB was expressed on
virus-reactive and total effector/memory CD8 T cells from day 3
to day 7. In contrast to VACV-Lister infection, although similar
to VACV-WR infection (Zhao and Croft, 2012), 4-1BB expression
was also found on ∼35% of viral antigen-speciﬁc CD8 T cells
7 days after B8R immunization (Figure 5A). After 3 weeks, we
found markedly increased accumulation of B8R-tetramer reactive
CD8 T cells and increased frequencies of functional B8R-reactive
cells assessed by staining for IFN-γ (Figures 5A,B). Again, this
was regardless of location (spleen versus lung). The activity was
most pronounced with a lower dose of anti-4-1BB, particularly
evident in IFN-γ producing cells in the lung, but both doses tested
strongly augmented the overall response. Next, we determined if
these elevated frequencies of CD8 T cells were functionally sig-
niﬁcant. Mice immunized with B8R peptide and injected with
FIGURE 5 | Anti-4-1BB promotes the accumulation of memory CD8T
cells followingVACV peptide immunization.WT mice were immunized s.c.
at the base of the tail with 2 μg of B8R peptide in IFA and 1 day later treated
with 25 or 150 μg anti-4-1BB or control Rat IgG. Control groups received
adjuvant but no peptide and antibody (PBS). (A) Gated CD8+CD44+ cells and
B8R-tetramer-positive CD8+ cells in spleens were stained for 4-1BB on days
3, 5, and 7 post-immunization. (B,C)Three weeks after immunization: (B) cells
from lung and spleen were stained with anti-CD8, -CD44, and B8R-tetramer.
Left: Representative dot plots of gated CD8+ cells. The numbers indicate the
percentage of CD8+CD44+B8R-tetramer-positive cells. Right: Total number
of CD8+CD44+B8R-tetramer-positive cells in the lung and spleen; (C) cells
from lung and spleen were stimulated with B8R peptide and stained for
intracellular IFN-γ. Total numbers of CD8+IFN-γ+ cells were calculated. Data
represent mean value ± SEM from n = 5 mice. Similar results were
reproduced in two separate experiments. Statistical signiﬁcance.
*p < 0.05.
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anti-4-1BB were subsequently exposed to a normally lethal dose
of VACV-WR given intranasally (Figure 6). We have previously
shown that protection against this mucosal infection can be medi-
ated exclusively by virus-speciﬁc CD8 T cells if their numbers
are sufﬁciently elevated in the lungs (Salek-Ardakani et al., 2008,
2011b). Immunization with peptide alone provided some pro-
tection in that ∼65% of mice survived, whereas treatment with
anti-4-1BB enhanced the resistance to infection. This was more
evident with low dose antibody treatment where 100% of mice
survived (Figure 6A), correlating with the increased frequency
of IFN-γ-producing CD8 T cells observed in the lungs above that
present in mice injected with the high dose of antibody (Figure 5).
No difference was observed in virus-induced pathology as assessed
by weight loss of the mice over the initial 5 days of infection,
however in mice surviving in either control or anti-4-1BB-treated
groups, the lower dose of anti-4-1BB allowed the mice to recover
their weight more quickly (Figure 6B). The latter suggested the
low dose of anti-4-1BB antibody enhanced the quality of protec-
tion and resistance was primarily due to the expanded numbers of
functional CD8 T cells.
Lastly, we immunized with two subdominant VACV epitopes,
N2L and B16R, again in IFA. Neither epitope alone was efﬁ-
cient in promoting the accumulation of epitope-reactive CD8 T
cells, and this translated into no protection against a subsequent
infection with VACV-WR (Figure 7). In contrast, anti-4-1BB
given with IFA immunization strongly enhanced the numbers of
IFN-γ-producingCD8Tcells thatwere generated, and engendered
signiﬁcant protection against infection with virulent virus. Thus,
targeting 4-1BB may also be applicable to promoting anti-viral
CD8 T cell populations induced by viral peptide vaccination as
well as by live or attenuated viruses.
DISCUSSION
Here, we show that treatment of mice with an agonist antibody
to 4-1BB strongly promotes the expansion and accumulation of
virus-speciﬁc primary effector CD8 T cells during infection with
live virulent and attenuatedVACV or with an immunization strat-
egy with VACV peptides. This suggests that targeting 4-1BB may
have application for boosting short-term CD8 T cell immunity
when used in a vaccine setting with vaccinia. We also show that
anti-4-1BB enhances the accumulation of VACV-speciﬁc memory
CD8T cells with live virulent virus andwith virus peptides given in
adjuvant, but not with attenuatedVACV. This further suggests that
targeting 4-1BB could be a useful strategy for long-term vaccina-
tion but that the type of vaccine may determine its usefulness and
additional factors may need to be promoted to allow agonists to
4-1BB to enhance memory CD8 T cells responses with attenuated
vaccinia viral vectors.
4-1BB has previously been shown to play a role in develop-
ment of CD8 T cell responses to a number of viruses, although
the requirement and stage of response for its activity has been
reported to be variable. 4-1BBL−/− mice were found to display
reduced CD8 T cell responses to both inﬂuenza virus and LCMV
Armstrong (DeBenedette et al., 1999; Tan et al., 1999; Bertram
FIGURE 6 | Anti-4-1BB promotes protective CD8T cells following
vaccination with an immunodominantVACV peptide.WT mice were
immunized s.c. at the base of the tail with 2 μg of B8R peptide in IFA and
injected with 25 or 150 μg anti-4-1BB antibody or rat IgG on day 1. Control
groups received adjuvant but no peptide and antibody (PBS). Three weeks
after vaccination, mice were infected intranasally with a lethal dose of
VACV-WR [3.5 × 106 PFU/mouse (300 × LD50)]. Animals were weighed
daily and were euthanized if they maintained a weight loss of 25% or
more for greater than 24 h. (A) Mean percent survival (n = 10–17/group).
(B) Body mass presented as the mean % ± SEM of initial body weight.
Data are pooled from three independent experiments with four to six
mice/group.
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FIGURE 7 | Anti-4-1BB promotes protective CD8T cells with vaccination
with subdominantVACV peptides.WT mice were immunized s.c. at the
base of the tail with 10 μg of N2L (A,C) or B16R (BD) peptide in IFA and
treated with 100 μg anti-4-1BB antibody or rat IgG as on day 1. (A,B) 7 days
after vaccination, splenocytes from N2L peptide vaccinated animals were
stimulated with N2L peptide, and splenocytes from B16R peptide vaccinated
animals were stimulated with B16R peptide. Total numbers of CD8+IFN-γ+
cells were calculated. Data represent mean value ± SEM from n = 5 mice.
(C,D)Three weeks after vaccination, mice were infected intranasally with a
lethal dose of VACV-WR [3.5 × 106 PFU/mouse (300 × LD50)]. Animals
were weighed daily and were euthanized if they maintained a weight
loss of 25% or more for greater than 24 h. Mean percent survival shown
(n = 9−12/group). Data are pooled from two independent experiments with
four to six mice/group. Statistical signiﬁcance. *p < 0.05.
et al., 2002, 2004), with the defect seen in some cases during
the primary response (Tan et al., 1999; Bertram et al., 2002), or
late during memory stabilization after a normal acute response
(DeBenedette et al., 1999), or primarily evident at the time of
reactivation of the memory cells (Bertram et al., 2004; Hendriks
et al., 2005). In other studies, 4-1BBL−/− mice immunized with
a lipidated version of an LCMV peptide had fewer primary and
memory epitope-speciﬁc CD8 T cells and were impaired in their
ability to resolve a subsequent LCMV infection (Tan et al., 2000).
4-1BBL−/− mice also generated functionally impaired CD8 T
cells during infection with latent mouse gammaherpesvirus-68
(MHV-68), but in this case their numbers were unaltered (Fuse
et al., 2007), and 4-1BBL−/− mice or wild-type mice injected with
a neutralizing antibody to 4-1BBL generated lower late but not
acute CD8 T cell responses to MCMV (Humphreys et al., 2010).
These data combined have given good rationale for targeting 4-
1BB in immunization or vaccination strategies for viruses as they
directly demonstrate that 4-1BB is available to act as a stimula-
tory receptor. Proof of concept studies targeting 4-1BB with an
agonist antibody, or 4-1BBL in a vector, consequently resulted in
enhanced CD8 responses to inﬂuenza, LCMV, and HSV (Halstead
et al., 2002; Kim et al., 2005; Zhang et al., 2007; Moraes et al., 2011;
Vezys et al., 2011).
Our scenario was different in that we found no endogenous
role for 4-1BB or 4-1BBL in driving a VACV-speciﬁc CD8 T cell
response in studies with either gene-deﬁcient mice or using a neu-
tralizing anti-4-1BBL antibody (Zhao and Croft, 2012). However,
we did ﬁnd that 4-1BB was expressed on theVACV-reactive CD8 T
cells shortly after infectionwithVACV-WR (Zhao andCroft, 2012)
providing an interesting test of whether targeting this molecule
would be efﬁcacious with VACV immunization. The assumption
by most in the ﬁeld is that the requirement for 4-1BB to augment
CD8 T cell expansion or activity is direct, based on in vitro data
showing 4-1BB can induce signals in CD8 T cells that promote
expression of cell cycle proteins and anti-apoptotic proteins (Can-
nons et al., 2001; Cooper et al., 2002; Lee et al., 2002, 2003; Nam
et al., 2005). 4-1BB can be expressed on a number of cell types
other than CD8 T cells, including activated CD4 T cells, NK cells,
and NKT cells. However, expression of 4-1BB on the responding
viral epitope-speciﬁc CD8 T cells is likely crucial for its activities
in promoting CD8 T cell priming. We showed this in several non-
viral models where TCR transgenic CD8 T cells lacking 4-1BB
were tracked during responses driven by anti-4-1BB and failed to
expand similar to wild-type T cells (Myers et al., 2006; Lee et al.,
2007). This does not rule out effects of 4-1BB signaling on other
cells but imply that expression of 4-1BB on the responding CD8
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T cells will be critical to any vaccine protocol that incorporates a
stimulant of this molecule.
Our data showed that anti-4-1BB effectively boosted primary
effector CD8 T cell responses regardless of strain of virus or pep-
tide immunization. These data extend other data with anti-4-1BB,
or 4-1BBL inserted into a vector, that similarly showed enhanced
initial priming of CD8 T cells to an HCV epitope expressed in ade-
novirus (Arribillaga et al., 2005) and to a DNA construct encoding
HIV Gag (Ganguly et al., 2010). In all cases, targeting 4-1BB was
effective in promoting either greater numbers of viral epitope-
reactive CD8 T cells or CD8 T cells that had greater CTL activity.
Interestingly, another study found that 4-1BBL inserted into a
recombinant fowlpox vector expressing HIV Gag did not have any
effect on augmenting a primary CD8 T cell response, but when it
was used to boost a response at 2 weeks, 4-1BBL expression signif-
icantly augmented the subsequent accumulation of HIV-reactive
CD8 T cells (Harrison et al., 2006). Why the latter study found no
activity in the initial priming of CD8 T cells is unclear, but it is
possible this was related to a lack of 4-1BB expression on the naïve
CD8 T cells responding to the fowlpox vector, although no studies
addressed this point.
Expression of 4-1BB may also be of relevance to our observa-
tions on memory generation. Although primary CD8 responses
were boosted regardless of VACV virus or peptide immunization,
we found the surprising result that anti-4-1BB only promoted
enhanced memory with VACV-WR and peptide/IFA immuniza-
tion but not with VACV-Lister. Although the explanation for this
is not known at present, we think there are two possibilities. The
ﬁrst is that 4-1BB may simply not have been expressed on viral
epitope-reactive CD8 T cells for a sufﬁcient length of time dur-
ing immunization with VACV-Lister. Whereas 4-1BB expression
was observed on ∼30% of viral antigen-speciﬁc cells over 7 days
with VACV-WR infection or IFA/peptide immunization, few CD8
T cells expressed 4-1BB at this time with VACV-Lister. In con-
trast to VACV-WR, which persists for a long time, VACV-Lister
is completely cleared from the ovaries between days 5 and 7 and
the spleen at day 3 (Salek-Ardakani et al., 2008, 2011a). Thus,
antigen persistence may result in prolonged expression of 4-1BB.
Transient 4-1BB expression likely translated to a brief period of
signaling from anti-4-1BB to augment clonal division in the effec-
tor cells, but the necessary pro-survival signals may not have been
induced that result from extended 4-1BB signaling and that might
be needed to allow greater accumulation of memory cells. Our
ﬁndings are reminiscent of a prior study (Lin et al., 2009) that
showed that 4-1BB expression on CD8 T cells was prolonged with
respiratory tract infection of a virulent inﬂuenza virus compared
to a milder inﬂuenza virus. This also correlated with a require-
ment for 4-1BB in the T cell response to the former, whereas
4-1BB was dispensable for the response to the less virulent strain.
Similarly, anti-4-1BB was previously shown to enhance primary
T cell responses to inﬂuenza virus delivered by the non-productive
i.p. route of infection, in which there is minimal viral replication,
but had little effect on the accumulation of T cells at later times
(Bertram et al., 2004). An alternative possibility is that attenu-
ated/less virulent viruses may not induce additional co-signals
that are needed to synergize with 4-1BB signals to augment T
cell memory. This notion is based on our previous studies in
non-viral systems where only peptide was used for immuniza-
tion, which results in little/no generation of memory CD8 T cells.
In one case, anti-4-1BB combined with a TLR3 ligand (poly IC)
resulted in accumulation of memory CD8 T cells, whereas the
agonist alone or the TLR3 ligand alone had no effect (Myers
et al., 2006). In another study, anti-4-1BB combined with a sec-
ond agonist to a different TNFR superfamily molecule, OX40, also
allowed the survival of polyfunctional CD8 T cells with peptide
immunization, whereas neither agonist alone was very effective
(Lee et al., 2007). Thus, anti-4-1BB might provide some of the
necessary survival signals that allow memory generation or per-
sistence, but additional synergistic signals from either cytokines
like IFN-α or IL-12 that might be induced by TLR ligands, or
from other TNFR family molecules, may be a prerequisite for this
activity. Therefore, sustained viral antigen presentation may reg-
ulate prolonged expression of 4-1BB on responding T cells, and
a long-lasting inﬂammatory environment may provide additional
co-signals that are needed for anti-4-1BB to promote memory.
The exact nature of any required co-signals might vary, but they
are likely to be provided by virulent viruses like VACV-WR and
certain inﬂuenza strains, but not by attenuated viruses such as
VACV-Lister, explaining the dichotomous results on memory gen-
eration. IFA immunization with peptide, as we performed in the
current study, most likely also allows sustained antigen presenta-
tion and provides an inﬂammatory environment that fulﬁlls both
of these requirements.
In summary, our studies demonstrate that targeting molecules
like 4-1BB may provide sufﬁcient adjuvant-type activities to allow
vaccination with attenuated poxvirus vectors or viral antigens to
promote effective short-term CD8 T cell immunity. However, our
results question whether targeting molecules like 4-1BB in isola-
tion will be sufﬁcient for allowing long-term CD8 T cell responses
to attenuated viruses or viral vectors, and warrant future studies of
combination targeting that could engender the appropriate signals
to also provide effective CD8 T cell memory.
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